SEC Comment Letter 0000000000-25-001232 to Skye Bioscience, Inc. (SKYE) (CIK 0001516551) (SKYE)
Skye Bioscience, Inc. (SKYE) (CIK 0001516551)
Date: Feb. 5, 2025 · CIK: 0001516551 · Accession: 0000000000-25-001232
AI Filing Summary & Sentiment
File numbers found in text: 000-55136
Letter
February 5, 2025 Kaitlyn Arsenault Chief Financial Officer Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Re:Skye Bioscience, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Form 10-Q for the Quarterly Period Ended September 30, 2024 File No. 000-55136 Dear Kaitlyn Arsenault: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 5, 2025
Kaitlyn Arsenault
Chief Financial Officer
Skye Bioscience, Inc.
11250 El Camino Real, Suite 100
San Diego, CA 92130
Re:Skye Bioscience, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Form 10-Q for the Quarterly Period Ended September 30, 2024
File No. 000-55136
Dear Kaitlyn Arsenault:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences